Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Advances in Therapy|January 31, 2023
Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical StudiesTakuo Kubota, Noriyuki Namba, Hiroyuki Tanaka, et al.
Bone|July 20, 2010
Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum periodMasanori Takaiwa, Kunihiko Aya, Takayuki Miyai, et al.
Bone|July 20, 2010
Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum periodMasanori Takaiwa, Kunihiko Aya, Takayuki Miyai, et al.
Endocrine Journal|September 25, 2012
An observational study of the effectiveness and safety of growth hormone (Humatrope(®)) treatment in Japanese children with growth hormone deficiency or Turner syndromeShigeru Tai, Toshiaki Tanaka, Tomonobu Hasegawa, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 23, 2020
Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced OsteomalaciaYasuo Imanishi, Nobuaki Ito, Yumie Rhee, et al.
European Journal of Pediatrics|May 15, 2017
Final adult height in long-term growth hormone-treated achondroplasia patientsDaisuke Harada, Noriyuki Namba, Yuki Hanioka, et al.
Clinical Pediatric Endocrinology : Case Reports and Clinical Investigations : Official Journal of the Japanese Society for Pediatric Endocrinology|October 14, 2017
Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)Susumu Yokoya, Tomonobu Hasegawa, Keiichi Ozono, et al.
Endocrine Journal|March 9, 2004
Clinical evaluation of recombinant human growth hormone in Noonan syndromeMasamichi Ogawa, Naoki Moriya, Hiroyuki Ikeda, et al.
Journal of Bone and Mineral Metabolism|July 13, 2021
Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23Nobuaki Ito, Takuo Kubota, Sachiko Kitanaka, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|October 8, 2020
Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatmentDaisuke Harada, Hiroko Kashiwagi, Kaoru Ueyama, et al.
Pageof 6